Multiple myeloma classification: Difference between revisions
No edit summary |
Shyam Patel (talk | contribs) No edit summary |
||
Line 7: | Line 7: | ||
==Classification== | ==Classification== | ||
Plasma cell disorders such as multiple myeloma and its related diseases are classified according to disease burden and the extent of organ involvement. | |||
:# | {| style="border: 0px; font-size: 90%; margin: 3px; width: 600px" align=center | ||
|valign=top| | |||
|+ | |||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Disease}} | |||
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Diagnostic Criteria}} | |||
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Management Approach}} | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | |||
[[Solitary plasmacytoma]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
Biopsy of solid mass showing clonal plasma cells | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
Radiation therapy | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | |||
[[Monoclonal gammopathy of undetermined significance]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*Presence of M-spike that quantitates < 3 g/dl on protein electrophoresis, ''or'' | |||
*Presence of bone marrow plasma cell burden of < 10% | |||
''plus'' | |||
*Absence of end-organ damage such as anemia, hypercalcemia, renal dysfunction, or osseous lesions | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
Monitoring of [[complete blood count]] every 6-12 months | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | |||
[[Smoldering multiple myeloma]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*Presence of M-spike that quantitates > 3 g/dl on protein electrophoresis, ''or'' | |||
*Presence of bone marrow plasma cell burden of > 10% but < 60% | |||
''plus'' | |||
*Absence of end-organ damage such as anemia, hypercalcemia, renal dysfunction, or osseous lesions | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
Monitoring of [[complete blood count]] at specified intervals, depending on risk stratification | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | |||
[[Active multiple myeloma]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*Presence of M-spike that quantitates > 3 g/dl on protein electrophoresis, ''or'' | |||
*Presence of bone marrow plasma cell burden of > 10% but < 60% | |||
''plus'' | |||
*Presence of at least one of the following: anemia, hypercalcemia, renal dysfunction, osseous lesions, bone marrow plasma cell burden > 60%, serum free light chain ratio (of involved to uninvolved light chain) > 100, MRI showing > 1 bony lesion of at least 5mm | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*Induction chemotherapy with bortezomib, lenalidomide, and dexamethasone | |||
*High-dose therapy plus autologous stem cell transplantation | |||
*Post-transplant lenalidomide maintenance | |||
(''Please see Therapy section for details'' | |||
|- | |||
|} | |||
==References== | ==References== |
Revision as of 04:27, 15 July 2018
Multiple myeloma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Multiple myeloma classification On the Web |
American Roentgen Ray Society Images of Multiple myeloma classification |
Risk calculators and risk factors for Multiple myeloma classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]
Overview
Multiple myeloma may be classified into several subtypes based on the extent of organ involvement (medullary or extramedullary) and the disease clinical presentation(active symptomatic or smoldering asymptomatic).[1]
Classification
Plasma cell disorders such as multiple myeloma and its related diseases are classified according to disease burden and the extent of organ involvement.
Disease | Diagnostic Criteria | Management Approach |
---|---|---|
Biopsy of solid mass showing clonal plasma cells |
Radiation therapy | |
plus
|
Monitoring of complete blood count every 6-12 months | |
plus
|
Monitoring of complete blood count at specified intervals, depending on risk stratification | |
plus
|
(Please see Therapy section for details |
References
- ↑ Alexiou C, Kau RJ, Dietzfelbinger H, Kremer M, Spiess JC, Schratzenstaller B; et al. (1999). "Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts". Cancer. 85 (11): 2305–14. PMID 10357398.